Multicenter Validation of CSF Neurofilaments As Diagnostic Biomarkers for ALS

Objective: Neurofilaments are leading neurochemical biomarkers for amyotrophic lateral sclerosis (ALS). Here, we investigated the effect of preanalytical factors on neurofilament concentrations in cerebrospinal fluid (CSF) in a "reverse" round-robin with 15 centers across Europe/U.S.

Methods: Samples from ALS and control patients (5/5 each center, n = 150) were analyzed for phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) at two laboratories.

Results: CSF pNfH was increased (p < 0.05) in ALS in 10 out of 15 centers and NfL in 5 out of 12 centers. The coefficient of variation (CV%) of pNfH measurements between laboratories was 18.7 ± 19.1%. We calculated a diagnostic cut-off of >568.5 pg/mL for pNfH (sensitivity 78.7%, specificity 93.3%) and >1,431pg/mL for NfL (sensitivity 79.0%, specificity 86.4%).

Conclusion: Values in ALS patients are already comparable between most centers, supporting eventual implementation into clinical routine. However, continuous quality control programs will be necessary for inclusion in the diagnostic work-up.

Citing Articles

Exploiting the role of CSF NfL, CHIT1, and miR-181b as potential diagnostic and prognostic biomarkers for ALS.

Gagliardi D, Rizzuti M, Masrori P, Saccomanno D, Del Bo R, Sali L J Neurol. 2024; 271(12):7557-7571.

PMID: 39340541 PMC: 11588799. DOI: 10.1007/s00415-024-12699-1.

Comparative analysis of neurofilaments and biomarkers of muscular damage in amyotrophic lateral sclerosis.

Vidovic M, Lapp H, Weber C, Plitzko L, Seifert M, Steinacker P Brain Commun. 2024; 6(5):fcae288.

PMID: 39239150 PMC: 11375854. DOI: 10.1093/braincomms/fcae288.

Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.

Vrillon A, Ashton N, Karikari T, Gotze K, Cognat E, Dumurgier J J Neurol. 2023; 271(3):1297-1310.

PMID: 37950758 DOI: 10.1007/s00415-023-12066-6.

Morphometric and Nanomechanical Screening of Peripheral Blood Cells with Atomic Force Microscopy for Label-Free Assessment of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

Taneva S, Todinova S, Andreeva T Int J Mol Sci. 2023; 24(18).

PMID: 37762599 PMC: 10531602. DOI: 10.3390/ijms241814296.

Exploring the role of cerebrospinal fluid as analyte in neurologic disorders.

Pingle S, Lin F, Anekoji M, Patro C, Datta S, Jones L Future Sci OA. 2023; 9(4):FSO851.

PMID: 37090492 PMC: 10116372. DOI: 10.2144/fsoa-2023-0006.